MedPath

Multi-Center Study of New Medications to Treat Vaginal Infections

Phase 3
Completed
Conditions
Vaginal Infection
Interventions
Drug: Metronidazole
Drug: Terconazole/metronidazole
Drug: Terconazole
Registration Number
NCT02308007
Lead Sponsor
Curatek Pharmaceuticals, LLC
Brief Summary

The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
475
Inclusion Criteria
  • A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
  • Capable of providing written informed consent or assent
  • Currently not menstruating and not anticipating menses during treatment
  • If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control
  • Negative pregnancy test
  • Other criteria as identified in the protocol
Read More
Exclusion Criteria
  • Other infectious causes of vulvovaginitis
  • Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
  • Nursing mother
  • Use of any investigational drug within 30 days of enrollment
  • History of hypersensitivity to any ingredient/component of the formulations
  • Other criteria as identified in the protocol
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Metronidazole vaginal gelMetronidazoleOne applicator full at bedtime
Terconazole/metronidazole vaginal gelTerconazole/metronidazoleOne applicator full at bedtime
Terconazole vaginal gelTerconazoleOne applicator full at bedtime
Primary Outcome Measures
NameTimeMethod
Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit7-14 days after beginning treatment

The percentage of participants with clinical cure of both bacterial vaginosis (BV) AND vulvovaginal candidiasis (VVC) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV is defined as: discharge has returned to normal/physiologic, negative whiff test, and saline wet mount is \<20% clue cells. Clinical cure of VVC is defined as resolution of all signs and symptoms attributable to vulvovaginal candidiasis

Secondary Outcome Measures
NameTimeMethod
Cure of the VVC Component of Mixed Infection7-14 days after beginning treatment

The percentage of participants with both BV and VVC who had clinical cure of VVC was compared between the combination therapy and the two single entity treatments.Clinical cure of VVC was defined as complete resolution of all signs and symptoms attributable to VVC

Microbiologic and Mycologic Cure7-14 days after beginning treatment

The percentage of participants with both microbiologic and mycologic cure was compared between the combination therapy and the two single entity treatments. Yeast cultures were performed and Gram stains of vaginal fluid were graded according to Nugent's criteria. Microbiologic cure requires normal Nugent gram stain score and mycologic cure requires negative yeast culture.

Cure of the BV Component of Mixed Infection7-14 days after beginning treatment

The percentage of participants with both BV and VVC who had clinical cure of bacterial vaginosis (BV) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV was defined as: 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells

Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit7-14 days after beginning treatment

Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.

Number of Participants With Treatment Emergent Adverse EventsAny time during study participation (up to 30 days)

Adverse events were collected at study visits, from subject diaries and from spontaneous reports

Trial Locations

Locations (51)

Georgia Regents University

🇺🇸

Augusta, Georgia, United States

Mount Vernon CLinical Research

🇺🇸

Sandy Springs, Georgia, United States

Women's Health Practice

🇺🇸

Champaign, Illinois, United States

Atlanta North Gynecology

🇺🇸

Roswell, Georgia, United States

Suffolk OB/GYN

🇺🇸

Port Jefferson, New York, United States

Wake Research Associates

🇺🇸

Raleigh, North Carolina, United States

Discovery Clinical Trials

🇺🇸

Dallas, Texas, United States

Signature Gyn Services

🇺🇸

Fort Worth, Texas, United States

Complete Healthcare for Women

🇺🇸

Columbus, Ohio, United States

Magee-Womens Hospital of UPMC

🇺🇸

Pittsburgh, Pennsylvania, United States

Texas Children's Hospital for Women

🇺🇸

Houston, Texas, United States

TMC Life Research, Inc.

🇺🇸

Houston, Texas, United States

Women's Clinical Research Center

🇺🇸

Seattle, Washington, United States

Harborview Medical Center

🇺🇸

Seattle, Washington, United States

MomDoc Womens Health Research

🇺🇸

Scottsdale, Arizona, United States

Rosemark Womens Care Specialists

🇺🇸

Idaho Falls, Idaho, United States

DelSol Research

🇺🇸

Tucson, Arizona, United States

NEA Baptist Clinic

🇺🇸

Jonesboro, Arkansas, United States

Precision Clinical Research

🇺🇸

Coral Springs, Florida, United States

Women's Health CT Ob/Gyn

🇺🇸

Bridgeport, Connecticut, United States

Southern Clinical Research Associates

🇺🇸

Metairie, Louisiana, United States

KO Clinical Research, LLC

🇺🇸

Fort Lauderdale, Florida, United States

Discovery Clinical Research

🇺🇸

Plantation, Florida, United States

Segal Institute for Clinical Research

🇺🇸

North Miami, Florida, United States

Comprehensive Clinical Trials, LLC

🇺🇸

West Palm Beach, Florida, United States

Praetorian Pharmaceutical Research, LLC

🇺🇸

Marrero, Louisiana, United States

Women's Health Research Center

🇺🇸

Plainsboro, New Jersey, United States

Women Under Study

🇺🇸

New Orleans, Louisiana, United States

Lawrence Ob/Gyn Clinical Research LLC

🇺🇸

Lawrenceville, New Jersey, United States

Women's Healthcare Specialists, PC

🇺🇸

Kalamazoo, Michigan, United States

Women's Clinic of Lincoln

🇺🇸

Lincoln, Nebraska, United States

Magnolia Ob/Gyn Research Center

🇺🇸

Myrtle Beach, South Carolina, United States

The Jackson Clinic

🇺🇸

Jackson, Tennessee, United States

James T. Martin, MD

🇺🇸

North Charleston, South Carolina, United States

Gossmont Center for Clinical Research

🇺🇸

La Mesa, California, United States

Drexel University

🇺🇸

Philadelphia, Pennsylvania, United States

Philapelphia Clinical Research, LLC

🇺🇸

Philadelphia, Pennsylvania, United States

East Carolina Women's Center

🇺🇸

New Bern, North Carolina, United States

Red Rocks Ob/Gyn

🇺🇸

Lakewood, Colorado, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Downtown Women's Health Care

🇺🇸

Denver, Colorado, United States

Legacy Women's Health

🇺🇸

Las Vegas, Nevada, United States

Genesis Center for Clinical Research

🇺🇸

San Diego, California, United States

Precision Trials, AZ

🇺🇸

Phoenix, Arizona, United States

Alabama Clinical Therapeutics

🇺🇸

Birmingham, Alabama, United States

Indiana University

🇺🇸

Indianapolis, Indiana, United States

University of Alabama

🇺🇸

Birmingham, Alabama, United States

Medical Center for Clinical Research

🇺🇸

San Diego, California, United States

Wayne State University

🇺🇸

Detroit, Michigan, United States

R. Garn Mabey Jr., MD Gynecology

🇺🇸

Las Vegas, Nevada, United States

Radiant Research

🇺🇸

Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath